Epidemiology of Autiommune and Metabolic Diseases

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Endocrinology".

Deadline for manuscript submissions: 20 August 2025 | Viewed by 936

Special Issue Editors


E-Mail Website
Guest Editor
2nd Internal Medicine Department, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
Interests: metabolic syndrome; deep vein thrombosis; peripheral vascular diseases

E-Mail Website
Guest Editor Assistant
2nd Internal Medicine Department, “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania
Interests: metabolic syndrome

Special Issue Information

Dear Colleagues,

Autoimmune disease incidence has been increasing in recent years due to the improved diagnosis rates. New therapies aim to improve the lifespan and improve the daily life quality of autoimmune disease patients.

Metabolic syndrome is one of the most rapidly growing health problems in highly developed countries, with obesity and sedentarism being the leading causes. It involves all the systems in the human organism and ranges from cardiovascular disease, gastroenterology, and neurology all the way to psychology-related disorders.

Genetic approaches to metabolic disorders are entering the “metabolism subject” in a new era of treatment.

This Special Issue will highlight the continuous changes in the incidence along with new approaches in the treatment and management of autoimmune and metabolic diseases.

We are collecting studies on autoimmune disease associations, metabolic disorders, and complications of autoimmune diseases. Also, studies on metabolic diseases (inherited or developed) are encouraged (including studies on inflammatory syndrome). The rare disease topic should cover autoimmune or metabolic disorders (including genetic research). Submissions on the associations of medical specialties and common approaches are encouraged. Medical or surgical overviews (including inter-specialty) reviews and meta-analysis are welcome.

In addition, submissions on quality of life, along with patient care systems and patient registries, will be considered for publication in this Special Issue.

Prof. Dr. Daniela Fodor
Guest Editor

Dr. Bogdan Augustin Chis
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • autoimmune system
  • metabolic syndrome
  • epidemiology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

12 pages, 1798 KiB  
Systematic Review
Atherogenic Index of Plasma in Metabolic Syndrome—A Systematic Review and Meta-Analysis
by Leia Mossane Andraschko, Gabi Gazi, Daniel-Corneliu Leucuta, Stefan-Lucian Popa, Bogdan Augustin Chis and Abdulrahman Ismaiel
Medicina 2025, 61(4), 611; https://doi.org/10.3390/medicina61040611 - 27 Mar 2025
Cited by 1 | Viewed by 721
Abstract
Background and Objectives: Numerous studies have explored the biomarker atherogenic index of plasma (AIP) in relation to metabolic syndrome (MetS), showing its potential utility in assessing this condition. However, the existing evidence remains inconsistent and inconclusive. Therefore, this study aimed to evaluate [...] Read more.
Background and Objectives: Numerous studies have explored the biomarker atherogenic index of plasma (AIP) in relation to metabolic syndrome (MetS), showing its potential utility in assessing this condition. However, the existing evidence remains inconsistent and inconclusive. Therefore, this study aimed to evaluate the association between AIP and MetS and assess its predictive accuracy. Materials and Methods: A comprehensive search of PubMed, EMBASE, and Scopus was conducted using a predefined search strategy to identify relevant studies. Eligible studies diagnosed MetS based on the International Diabetes Federation criteria. The primary outcomes were the mean difference (MD) in AIP between MetS patients and healthy controls, as well as the area under the curve (AUC) for AIP in predicting MetS. Results: Thirteen studies involving 17,689 participants met the inclusion criteria and were included in the systematic review and meta-analysis. AIP levels were significantly higher in MetS patients compared to healthy controls, with an MD of 0.309 (95% CI 0.214, 0.405). In contrast, the difference in AIP levels between type 2 diabetes mellitus (T2DM) patients with MetS and normoglycemic MetS patients was not statistically significant (MD 0.142, 95% CI −0.091, 0.376). The predictive accuracy of AIP for MetS yielded an AUC of 0.864 (95% CI 0.856, 0.871). Conclusions: AIP levels are significantly elevated in MetS patients compared to healthy individuals, supporting AIP’s potential role as a biomarker for MetS. However, AIP levels did not differ significantly between T2DM patients with MetS and normoglycemic MetS patients. The predictive accuracy of AIP for MetS is acceptable, indicating that AIP may serve as a useful tool in MetS diagnosis. Further research is warranted to clarify its diagnostic and prognostic significance in clinical settings. Full article
(This article belongs to the Special Issue Epidemiology of Autiommune and Metabolic Diseases)
Show Figures

Figure 1

Back to TopTop